An innovative service company focusing on the field of drug quality control

News

Contact Us

You are here:Home >> News >> Industry information...

Industry information

Update to living WHO guideline on drugs for covid-19

Time:2022-04-26 Views:549
The World Health Organization (WHO) has released the ninth update of their living guideline on medications for the treatment of COVID-19 infection. These updates were published in BMJ (A living WHO guideline on drugs for covid-19).


In this update the Guideline Development Group (GDG) developed new recommendations for patients with non-severe covid-19, concerning the use of nirmatrelvir/ritonavir and remdesivir.

New recommendation
Strong recommendation for the use of nirmatrelvir-ritonavir in patients with non-severe illness at the highest risk of hospitalization.
Conditional recommendation against the use of nirmatrelvir-ritonavir in patients with non-severe illness at a low risk of hospitalization.
Conditional recommendation for the use of remdesivir in patients with non-severe COVID-19 at the highest risk of hospitalization.

To support your research and analysis of drugs for covid-19, we supply a range of nirmatrelvir-related impurities, ritonavir-related impurities and remdesivir-related impurities standards with certified COA and characterization data like Mass, HPLC, NMR & TGA report. 

Discover all our products through our official website, and get in touch if you have any questions about how we can help support your work. Email:sale@ex-biotech.com.
  • Previous:Nothing
  • Next:Nothing